AUTHORS
Shunzhe Xu, Chongsheng Qian2, Zheng Li, PhD3, Zhen Yao4, Yang Zhang5, Leisi Zhang6, Wenjie Gong7, Lan Dai8, Aining Sun9, Depei Wu Sr, MD10, Shengli Xue11
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, Suzhou, China
2 The First Affiliated Hospital of Soochow University, Suzhou, China
3 The First Affiliated Hospital of Soochow University, Suzhou, China
4 The First Affiliated Hospital of Soochow University, Suzhou, China
5 Canglang Hospital of Suzhou, Suzhou, China
6 The First Affiliated Hospital of Soochow University, Suzhou, China
7 The First Affiliated Hospital of Soochow University, Suzhou, China
8 The First Affiliated Hospital of Soochow University, Suzhou, China
9 The First Affiliated Hospital of Soochow University, Suzhou, China
10 The First Affiliated Hospital of Soochow University, Suzhou, China
11 The First Affiliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Author notes:
#Correspondence:
Sheng-Li Xue, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi Street 188, Suzhou 215006, P.R. China.
Email: slxue@suda.edu.cn
Background: Recent clinical studies have demonstrated favorable efficacy and safety profiles for blinatumomab, inotuzumab ozogamicin(INO) and CART in B-ALL patients. BLAST study (showing 78% MRD negativity after one blinatumomab cycle) and D-ALBA study(increasing deep remission from 60% to 81% with two additional cycles) highlight blinatumomab’s effectiveness in inducing deep remissions.The pivotal Phase III INO-VATE trial (showing 80% CR rate and 78% MRD negativity among responders with inotuzumab ozogamicin) highlights inotuzumab ozogamicin’s superior efficacy over standard chemotherapy in R/R B-ALL.CAR-T cell therapy has been predominantly applied in relapsed/refractory B-ALL, achieving high remission rates but with a high risk of frequent relapses, while early-phase application is rarely explored. Zhang et al reported encouraging efficacy,with a 76% complete molecular remission (CMR) rate achieved by dasatinib and CAR T-cell therapy in newly diagnosed patients with Ph-positive B- ALL.We therefore initiated a phase II trial evaluating an immunotherapy combined with Auto-HSCT and CD22/CD19 CAR-T “Sandwich” Strategy in B-ALL patients.
METHODS: This multicenter, single-arm, open-label study (NCT06985498) enrolled CD19/CD22+ B-ALL AYA/adult patients ineligible for or declining allo-HSCT. All patients or guardians have signed an informed consent form before the commencement of the study. Patients first receive standard chemotherapy as induction therapy, followed by immunotherapies as consolidation therapy. Relapsed or refractory patients directly receive immunotherapies. Minimal Residual Disease (MRD) was evaluated by multicolor flow cytometry (MFC-MRD) and next-generation sequencing of IgH rearrangement (NGS-MRD) after immunotherapies. Immunotherapies include blinatumomab, inotuzumab ozogamicin and CD22/CD19 CAR-T cell. In principle, these three treatment options are administered sequentially. Once patients achieve dual negativity of MFC-MRD and NGS-MRD, no further immunotherapies are applied, and patients proceed to autologous stem cell mobilization and collection. Prior to autologous stem cell transplantation (Auto-HSCT) , patients receive high-dose MTX for CNS prophylaxis. CD22/CD19 CAR-T cells are infused 2 days after stem cell infusion. Patients with ph positive and ph-like (ABL class) B-ALL require TKIs. The primary endpoint was OS, and LFS and CIR were the secondary endpoints.
Results: Up to the last follow-up on July 1, 2026, a total of 16 patients were enrolled, 10 were diagnosed as Philadelphia chromosome negative (Ph-) B-ALL and 6 were diagnosed as Philadelphia chromosome positive (Ph +) B-ALL. Nine patients had high-risk genetic characteristics. After induction consolidation chemotherapy, 75% (12/16) of patients achieved complete response (CR), 56% reached MFC-MRD negative, and 13% reached NGS-MRD negative. After the first cycle of blinatumumab, all 16 evaluable patients achieved CR, 94% (15/16) were negative for MFC-MRD and 63% (10/16) were negative for NGS-MRD. Five patients with MFC-MRD or NGS-MRD positive received intensive therapy(inotuzumab ozogamicin and CART), 80%(4/5) reached MFC-MRD and NGS-MRD double negative, and one patient was withdrawn due to persistently positive NGS-MRD After auto-HSCT + CD22/CD19 CART treatment (11 patients evaluated), 100% of patients remain NGS-MRD negative CR and no severe cytokine release syndrome (CRS) and ICANS occurred in the cohort. At a median follow-up of 9 months, 15 (100%) patients remained alive and in complete response (CR) and 13 (87%) patients remained NGS-MRD negative CR. Two patients who had NGS-MRD positive after auto-HSCT + CD22/CD19 CART received blinatumumab and achieved NGS-MRD negative.
Conclusion: Immunotherapy combined with Auto-HSCT and CD22/CD19 CAR-T “Sandwich” Strategy demonstrates a promising approach for B-ALL in AYA and adult patients, achieving high efficacy with a favorable safety profile. Further validation through larger cohorts and long follow-up is needed.
DISCLOSURES
Shunzhe Xu: No relevant conflicts of interest to declare.